aHUS

Atypical haemolytic uremic syndrome (aHUS)

Learn more about aHUS, a form of thrombotic microangiopathy (TMA) caused by overactivation of the terminal complement system^1,2

Diagnosing aHUS

Discover the key steps in the diagnosis of aHUS

Symptoms of aHUS

Recognise the common signs and symptoms of aHUS

Living with aHUS

Understand the impact of aHUS on the person with the condition and their caregivers

ULTOMIRIS^® is indicated in the treatment of adult and paediatric patients with a body weight of 10 kg or above with aHUS who are complement inhibitor treatment-naïve or have received eculizumab for at least 3 months and have evidence of response to eculizumab.³

Please consult the Summary of Product Characteristics prior to prescribing.

About ULTOMIRIS®

ULTOMIRIS^® in the treatment of atypical haemolytic uremic syndrome (aHUS)

MECHANISM of action

Review and explore the mechanism of action of ULTOMIRIS^®

Efficacy

Explore clinical data looking at the efficacy of ULTOMIRIS^®

SAFETY

Explore clinical data looking at the safety of ULTOMIRIS^®

Dosing calculator

Access our easy-to-use tool to calculate your patient's dosing requirements

Sign up now to be informed of our upcoming symposia, our latest educational updates, and to be alerted to our webinars, hosted by world leading experts in aHUS.

Keep me up to date

FIRST NAME*

SURNAME*

DISEASE AREA OF INTEREST*

Specialty*

EMAIL*

COUNTRY*

Electronic messaging: I agree and consent that Alexion can send via email or other electronic messaging, such as SMS or fax, information about rare diseases, about approved products and services of Alexion, invitations to webinars, information about scientific events and/or other scientific information by Alexion and its affiliates, based on your needs. Before consenting, please read our privacy notice.

Dosing and administration

Learn about the weight-based dosing regimen of ULTOMIRIS^®

webinars

Leading experts in aHUS present educational updates in our latest webinar series

e-publications

Navigate through recent publications on aHUS and ULTOMIRIS^®

LIVING WITH aHUS

Understand the impact that aHUS may have on patients and their caregivers

I am a healthcare professional registered in the EU

I am not a
healthcare professional

Adverse Event Reporting

Please report any adverse events via your national reporting system. Adverse events can also be reported to Alexion Pharmaceuticals by contacting: https://contactazmedical.astrazeneca.com/

aHUS, atypical Atypical haemolytic uremic syndrome; TMA, thrombotic microangiopathy

Laurence J, et al. Clin Adv Hematol Oncol. 2016;14:2–15

Azoulay E, et al. Chest. 2017;152:424–434

ULTOMIRIS^® EU Summary of Product Characteristics available at https://www.ema.europa.eu/en/documents/product-information/ultomiris-epar-product-information_en.pdf. Last accessed: January 2024.